all the information, none of the junk | biotech • healthcare • life sciences

AVI Nails Down $30M

AVI Biopharma, the Bothell, WA-based developer of RNA therapies, said today it has raised another $30 million through a stock offering. The company (NASDAQ: AVII) said it sold 21 million new shares of common stock, in addition to 8.5 million warrants to buy shares, in an offering underwritten by Jefferies & Company. AVI, which recently moved its headquarters from Portland, OR to Bothell, has raised money from a variety of foundations, and government agencies to support its experimental treatments for Duchenne Muscular Dystrophy, and Ebola virus.